Jupiter Topco LLC Takes Position in Edwards Lifesciences Corporation $EW

Posted by George Bondi on Aug 27th, 2026

Jupiter Topco LLC acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,240,222 shares of the medical research company’s stock, valued at approximately $112,188,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. TrinityBridge Ltd purchased a new stake in Edwards Lifesciences during the second quarter valued at $27,000. MV Capital Management Inc. bought a new position in Edwards Lifesciences in the fourth quarter valued at about $26,000. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences in the first quarter worth about $25,000. Kemnay Advisory Services Inc. purchased a new position in Edwards Lifesciences in the fourth quarter worth about $27,000. Finally, JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $25,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $90.93 on Thursday. The company has a market capitalization of $52.36 billion, a P/E ratio of 52.26, a P/E/G ratio of 2.38 and a beta of 0.85. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The firm’s 50 day simple moving average is $89.43 and its two-hundred day simple moving average is $84.91. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period last year, the firm earned $0.67 EPS. The company’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,425 shares of company stock valued at $219,199 in the last quarter. 0.31% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Truist Financial boosted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Citigroup upped their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. BTIG Research lifted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Finally, Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Check Out Our Latest Analysis on Edwards Lifesciences

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.